Table 3 Outcomes of treatment for the MSC-treated and placebo-treated patients.
Items | MSC group | Placebo group | P valuea |
|---|---|---|---|
Clinical improvement rates | |||
Day 7 | 0.031 | ||
Symptom remissionb | 11 (37.9) | 4 (13.8) | |
Improvement | 17 (58.6) | 19 (65.5) | |
No improvement | 1 (3.4) | 6 (20.7) | |
Day 14 | 0.0466 | ||
Symptom remission | 19 (65.5) | 12 (41.4) | |
Improvement | 9 (31.0) | 10 (34.5) | |
No improvement | 1 (3.4) | 7 (24.1) | |
Day 21 | 0.0187 | ||
Symptom remission | 21 (72.4) | 16 (55.2) | |
Improvement | 8 (27.6) | 6 (20.7) | |
No improvement | 0 | 7 (24.1) | |
Chest image results based on CT and X-ray | |||
Patients with common/mild COVID-19 | |||
Day 7 | 0.5756 | ||
Improvement | 6 (20.7) | 7 (24.1) | |
Progression-free | 8 (27.6) | 9 (31.0) | |
Progression | 1 (3.4) | 0 | |
Day 14 | 0.3171 | ||
Improvement | 6 (20.7) | 7 (24.1) | |
Progression-free | 7 (24.1) | 9 (31.0) | |
Progression | 2 (6.9) | 0 | |
Day 21 | 0.5436 | ||
Improvement | 7 (24.1) | 7 (24.1) | |
Progression-free | 7 (24.1) | 9 (31.0) | |
Progression | 1 (3.4) | 0 | |
Patients with severe/critical COVID-19 | |||
Day 7 | 0.0099 | ||
Improvement | 10 (34.5) | 2 (6.7) | |
Progression-free | 4 (13.8) | 9 (31.0) | |
Progression | 0 | 2 (6.7) | |
Day 14 | 0.0754 | ||
Improvement | 9 (31.0) | 3 (10.3) | |
Progression-free | 4 (13.8) | 6 (20.7) | |
Progression | 1 (3.4) | 4 (13.8) | |
Day 21 | 0.0084 | ||
Improvement | 11 (37.9) | 3 (10.3) | |
Progression-free | 3 (10.3) | 6 (20.7) | |
Progression | 0 | 4 (13.8) | |
Median time required for symptoms remissionc | |||
7 (7, 12) | 13 (8, 16) | 0.0194d | |
Median time of hospital stayc | |||
11 (8, 14) | 15 (11, 19) | 0.0198d | |
